Jazz Fails to Nix Avadel Antitrust Claims in Sleep-Drugs Clash

Avadel Pharmaceuticals Plc’s antitrust claims against Jazz Pharmaceuticals Plc advanced toward trial in a case over whether Jazz misused a patent registry to try to block Avadel’s rival to its Xyrem narcolepsy drug.

Avadel offered enough evidence of antitrust standing and Jazz’s potential liability to send the dispute to a jury, Judge Gregory B. Williams wrote in an opinion Monday denying Jazz’s motions for summary judgment on Avadel’s counterclaims in the US District Court for the District of Delaware. A jury trial is set to begin Nov. 3.

Jazz sued in 2021 alleging Avadel’s once-nightly treatment Lumryz—at the time, a ...